New drug cocktail aims to tackle returning myeloma
NCT ID NCT06785415
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a combination of four drugs—iberdomide, daratumumab, elotuzumab, and dexamethasone—in people whose multiple myeloma has come back after treatment. The study has two phases: first, finding the safest dose of iberdomide, and second, seeing how well the combo works at shrinking tumors. About 37 participants will be enrolled, all of whom have had up to three prior treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iberdomide, daratumumab, elotuzumab, and dexamethasone
What this could lead to
If it works, this could offer a new treatment option for people whose multiple myeloma has returned after prior therapies.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact